Investment
Features
FeesSafety
Academy
More
Pluang+

XRP price dips to $1.51 amid ongoing XRP Ledger lending proposal votes.

Protocol Fundamentals
23 Sep 2026
Crypto news
View Source
Neutral
XRP price dips to $1.51 amid ongoing XRP Ledger lending proposal votes.

XRP price briefly rose above $1.65 before falling back to around $1.51 on September 23, with $1.60 as a key resistance level. The XRP Ledger is currently voting on two lending proposals, XLS-65 and XLS-66, which would enable pooled vaults and fixed-term lending but require over 80% validator approval to activate. These changes could increase XRP usage but have no confirmed start date yet. XRP remains above its 20-day moving average near $1.40, though money flow is negative, indicating cautious investor sentiment.

XRP Ledger lending plan progress provides context alongside Pluang's market data as of Sep 23, 2026 23:05 WIB. Among 50 major cryptocurrencies on Pluang, only 8 rose while 41 fell. Notably, DOT (Polkadot) dropped 7.28% to Rp19.423 with 72% sell orders, ADA (Cardano) declined 6.58% to Rp4.215 with 78% sell orders, and ALGO (Algorand) decreased 6.37% to Rp1.851 but saw 61% buy orders, contrasting with the broader sell sentiment.

More News

GE Aerospace stock could rise 35% as analysts highlight strong backlog and new engine orders.

GE Aerospace stock could rise 35% as analysts highlight strong backlog and new engine orders.

Jefferies analysts set a new price target of $435 for General Electric Aerospace, implying a 35% upside from its current price of around $321. GE Aerospace's strong position is supported by a $170 billion commercial services backlog and 80,000 aircra...

Analyst Insights
Bullish
2 hours ago
BNP Paribas cuts PepsiCo price target to $161, citing demand challenges but keeps Outperform rating.

BNP Paribas cuts PepsiCo price target to $161, citing demand challenges but keeps Outperform rating.

BNP Paribas lowered its price target for PepsiCo from $183 to $161 on September 23, 2026, due to ongoing demand challenges in North America. Despite the cut, the firm maintained an Outperform rating, indicating confidence in the stock's potential. Th...

Analyst Insights
Bearish
3 hours ago
Celldex's price target jumps to $88 after positive Phase III trial for chronic urticaria drug.

Celldex's price target jumps to $88 after positive Phase III trial for chronic urticaria drug.

Celldex Therapeutics saw its price target raised from $70 to $88 by Leerink Partners following successful Phase III trial results for its drug barzolvolimab treating chronic spontaneous urticaria (CSU). The trials met all primary endpoints, showing l...

Analyst Insights
Bullish
3 hours ago
Ero Copper stock holds steady with a raised price target amid plans to boost production by 2028.

Ero Copper stock holds steady with a raised price target amid plans to boost production by 2028.

Ero Copper, a major copper producer, shows stock volatility between $16.88 and $40.83 over the past year. Analyst firm CIBC maintained a "Neutral" rating but increased the price target to C$56.00, reflecting optimism about the company's long-term gro...

Analyst Insights
Bullish
3 hours ago
Cintas reports strong Q1 with EPS $1.39 and revenue up 10.9%, beating estimates.

Cintas reports strong Q1 with EPS $1.39 and revenue up 10.9%, beating estimates.

Cintas Corporation posted robust first-quarter results, surpassing analyst expectations with earnings per share of $1.39 and revenue of $3.01 billion, a 10.9% increase year-over-year. The company's organic revenue growth was 8.9%, reflecting solid bu...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App